# A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Placebo in T2DM Patients

Study · id `cardio:ct-nct05680155` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05680155](<https://clinicaltrials.gov/study/NCT05680155>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05680155

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 211 participants.

## Technical summary

Registry record NCT05680155. Randomized; double masking; primary purpose treatment. Start 2022-12-29 (actual); primary completion 2024-06-12 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 211 participants (enrolled count; ClinicalTrials.gov record NCT05680155, source copy `cardio:ctgov-nct05680155-2025-09-10`, retrieved 2026-10-26)
- Started: 2022-12-29 (actual) (ClinicalTrials.gov record NCT05680155, source copy `cardio:ctgov-nct05680155-2025-09-10`, retrieved 2026-10-26)
- Primary completion: 2024-06-12 (actual) (ClinicalTrials.gov record NCT05680155, source copy `cardio:ctgov-nct05680155-2025-09-10`, retrieved 2026-10-26)
- Completion: 2024-10-12 (actual) (ClinicalTrials.gov record NCT05680155, source copy `cardio:ctgov-nct05680155-2025-09-10`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT05680155, source copy `cardio:ctgov-nct05680155-2025-09-10`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05680155-2025-09-10`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Placebo in T2DM Patients
- Condition: T2DM
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Ecnoglutide
- Intervention (Drug): Placebo
- Lead sponsor: Hangzhou Sciwind Biosciences Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy and safety of cAMP signalling-biased GLP-1 analogue ecnoglutide monotherapy versus placebo in patients with type 2 diabetes (EECOH-1): a multi-centre, randomised, double-blind, placebo-controlled, phase 3 trial (`cardio:pubmed-41501026`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: a9dc39cc6e035b70b2c0df7255156706e141c22e3494aa50fb25dd85ae7cc564
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
